Pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis, representing one risk factor for PDAC, are characterized by a marked desmoplasia enriched of pancreatic myofibroblasts (PMFs). Thus, PMFs are thought to essentially promote pancreatic tumorigenesis. We recently demonstrated that the adhesion molecule L1CAM is involved in epithelial-mesenchymal transition of PMF-cocultured H6c7 human ductal epithelial cells and that L1CAM is expressed already in ductal structures of chronic pancreatitis with even higher elevation in primary tumors and metastases of PDAC patients. This study aimed at investigating whether PMFs and L1CAM drive malignant transformation of pancreatic ductal epithelial cells by enhancing their tumorigenic potential. Cell culture experiments demonstrated that in the presence of PMFs, H6c7 cells exhibit a profound resistance against death ligand-induced apoptosis. This apoptosis protection was similarly observed in H6c7 cells stably overexpressing L1CAM. Intrapancreatic inoculation of H6c7 cells together with PMFs (H6c7co) resulted in tumor formation in 7/8 and liver metastases in 6/8 severe combined immunodeficiency (SCID) mice, whereas no tumors and metastases were detectable after inoculation of H6c7 cells alone. Likewise, tumor outgrowth and metastases resulted from inoculation of L1CAM-overexpressing H6c7 cells in 5/7 and 3/7 SCID mice, respectively, but not from inoculation of mock-transfected H6c7 cells. Treatment of H6c7co tumor-bearing mice with the L1CAM antibody L1-9.3/2a inhibited tumor formation and liver metastasis in 100 and 50%, respectively, of the treated animals. Overall, these data provide new insights into the mechanisms of how PMFs and L1CAM contribute to malignant transformation of pancreatic ductal epithelial cells in early stages of pancreatic tumorigenesis.
Pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis, representing one risk factor for PDAC, are characterized by a marked desmoplasia enriched of pancreatic myofibroblasts (PMFs). Thus, PMFs are thought to essentially promote pancreatic tumorigenesis. We recently demonstrated that the adhesion molecule L1CAM is involved in epithelial-mesenchymal transition of PMF-cocultured H6c7 human ductal epithelial cells and that L1CAM is expressed already in ductal structures of chronic pancreatitis with even higher elevation in primary tumors and metastases of PDAC patients. This study aimed at investigating whether PMFs and L1CAM drive malignant transformation of pancreatic ductal epithelial cells by enhancing their tumorigenic potential. Cell culture experiments demonstrated that in the presence of PMFs, H6c7 cells exhibit a profound resistance against death ligand-induced apoptosis. This apoptosis protection was similarly observed in H6c7 cells stably overexpressing L1CAM. Intrapancreatic inoculation of H6c7 cells together with PMFs (H6c7co) resulted in tumor formation in 7/8 and liver metastases in 6/8 severe combined immunodeficiency (SCID) mice, whereas no tumors and metastases were detectable after inoculation of H6c7 cells alone. Likewise, tumor outgrowth and metastases resulted from inoculation of L1CAM-overexpressing H6c7 cells in 5/7 and 3/7 SCID mice, respectively, but not from inoculation of mock-transfected H6c7 cells. Treatment of H6c7co tumor-bearing mice with the L1CAM antibody L1-9.3/2a inhibited tumor formation and liver metastasis in 100 and 50%, respectively, of the treated animals. Overall, these data provide new insights into the mechanisms of how PMFs and L1CAM contribute to malignant transformation of pancreatic ductal epithelial cells in early stages of pancreatic tumorigenesis.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumor diseases exhibiting an unfavorable prognosis. In Western countries, PDAC ranked 4th in the order of fatal tumor diseases with a still increasing prevalence (1) . Owing to the lack of specific symptoms, PDAC is mostly detected in an advanced stage when the tumor has already metastasized and therapeutic options are limited accounting for an overall 5 years survival rate of 2% (2) .
Most PDACs are thought to arise from the ductal epithelium. One hallmark of PDAC is its pronounced desmoplasia (tumor stroma) mainly consisting of activated fibroblasts [also designated as myofibroblasts, activated pancreatic stellate cells or carcinoma-associated fibroblasts (CAF)] and extracellular matrix proteins. This marked desmoplasia is already present in chronic pancreatitis (3) (4) (5) , which represents one risk factor for PDAC (3, 4) . Besides genetic alterations, e.g. in the k-ras, p53 or DPC4/Smad4 genes, continuous interactions between ductal and, later on, carcinoma cells and the stromal environment are important for PDAC tumorigenesis (6) (7) (8) . Guerra et al. (9) showed that expression of mutant k-Ras G12V in acinar and centroacinar cells of adult mice did not result in the development of Pancreatic Intraepithelial Neoplasias (PanINs) and invasive PDAC unless the animals undergo a chronic pancreatitis indicating that genetic alterations in somatic cells alone do not necessarily lead to neoplastic formation. Moskovitz et al. (10) demonstrated that chronic exposure to oxidative stress which is likely to occur during chronic inflammation can induce chromosomal alterations in cultured normal pancreatic ductal epithelial cells. Accordingly, genomic instability in terms of chromosomal and gene abnormalities could be detected already in earliest PanIN lesions and tissues of chronic pancreatitis (10, 11) . In addition, the epithelial-mesenchymal transition (EMT) is supposed to promote tumorigenesis. Upon this process, epithelial and carcinoma cells, respectively, lose their epithelial phenotype by acquiring a spindle-shaped morphology and exhibiting a reduced expression of the epithelial-specific surface molecule E-cadherin, whereas the expression of mesenchymal marker proteins such as vimentin and N-cadherin is elevated (12, 13) . These alterations are thought to be prerequisite for cell dissociation from the epithelial tissue consequently leading to metastasis. One important inducer of EMT is the transforming growth factor-beta 1 (TGF-b1) which can be released by both stroma and tumor cells leading to a paracrine loop by which malignancy associated alterations of the stroma and tumor are promoted. Thus, tumor cell-derived TGF-b1 leads to activation of fibroblasts/stellate cells and promotes desmoplastic reaction. Secretion of TGF-b1 by MFs (activated pancreatic stellate cells/CAFs) fosters EMT in the tumors cells and thereby tumor progression (14) (15) (16) (17) . Using the human pancreatic ductal cell line H6c7, we recently demonstrated that coculture with pancreatic myofibroblasts (PMFs) led to TGF-b1-dependent EMT being associated with an upregulation of the adhesion molecule L1CAM (18) . Moreover, as a result of this elevated L1CAM expression, H6c7 cells acquire a chemoresistant and migratory phenotype (18) . L1CAM (CD171) is a member of the immunoglobulin superfamily and has been detected in a variety of tumors such as melanoma, colon cancer as well as in PDAC (19) (20) (21) (22) (23) (24) being associated with poor prognosis and short survival times (21, 24, 25) . Several studies demonstrated an involvement of L1CAM in various biological processes of tumorigenesis such as tumor cell migration and invasion, chemoresistance as well as tumor growth and survival (18) (19) (20) 22, 26) pointing to an important role of this protein in the development and progression of tumors.
H6c7 cells do not harbor established mutations in oncogenes or tumor suppressor genes (27) (28) (29) regarded as initial events in pancreatic tumorigenesis. Moreover, they are described to be non-tumorigenic and our recent data support the hypothesis that (i) malignant transformation of pancreatic ductal epithelial cells might be initiated before genetic aberrations occur and (ii) PMFs and L1CAM play an essential role in this scenario. Based on these findings, the present study aimed at elucidating whether the PMF-and L1CAM-mediated alterations of ductal epithelial cells relates to an increased tumor formation and metastasis in vivo.
Material and methods

Cell lines and cell culture
The human pancreatic ductal epithelial cell line H6c7 (kindly provided by Prof. M.S. Tsao, Ontario Cancer Center, Toronto, Canada) was cultured as described (30) . For some experiments, H6c7 cells were retrovirally transduced either with an empty vector (mock) or with a vector encoding human L1CAM (31) . Before transduction, the L1CAM construct was verified by sequencing. The transduction procedure with retroviral vectors and the selection of transduced clones with puromycin were described previously (32) .
Pancreatic fibroblasts
Murine myofibroblasts (PMFs) were isolated and cultured as described (8) . The myofibroblastic phenotype was confirmed by immunocytochemical staining for vimentin and a-smooth muscle actin. Since the in vivo experiments were performed with PMFs, the in vitro experiments were mainly done with murine PMFs and confirmative experiments were performed with human PMFs (see Supplementary Data, available at Carcinogenesis Online).
Coculture
For coculture, 1 Â 10 5 H6c7 cells in 2 ml H6c7 medium were seeded into a well of a six-well-plate and 2 Â 10 5 PMFs in 1.5 ml PMF medium were seeded into a transwell insert (0.4 lm pore size; Greiner, Frickenhausen, Germany) which was placed into a well with H6c7 cells. After 24 h, medium was exchanged. To continue the coculture for 4 weeks with PMFs (for human PMFs, see Supplementary Data, available at Carcinogenesis Online), cells were seeded as described above. Then, every week cocultured H6c7 cells and cocultured PMFs were detached, counted and freshly seeded at the respective cell numbers. In parallel, H6c7 cells were cultured in the absence of PMFs (H6c7mono) under the same conditions.
Antibodies and reagents
The mouse anti-human L1-9.3/2a antibody binding to the ectodomain of L1CAM has been described earlier (33) . Mouse IgG2a control antibodies (clone Cl.18) were purchased from BioXCell (West Lebanon, NH). Killer tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was purchased from Alexis Biochemicals (Grünberg, Germany) and the agonistic anti-CD95/Fas antibody CH-11 was obtained from Coulter Immunotech (Hamburg, Germany). Both reagents were used at a final concentration of 0.1 lg/ml. Human tumor necrosis factor-a was from Sigma-Aldrich Chemie (Taufkirchen, Germany) and used at a final concentration of 20 ng/ml.
Measurement of apoptosis by determination of caspase-3/-7 activity For determination of apoptosis, cells were either left untreated or were treated as indicated. Twenty-four hours after treatment, caspase-3/-7 activity was determined by using a kit from Promega (Mannheim, Germany) according to the manufacturer's instructions and as described previously (8, 22) . All assays were done in duplicates. Data are expressed as n-fold treatment induced caspase-3/-7 activity (over basal) related to the cell number, which was determined in parallel.
Tumor model and therapy
All animal experiments have been approved by the local ministry and were performed in the central animal facility of the University Hospital SchleswigHolstein under pathogen-free conditions. All experiments were assessed in 4-to 6-week-old female SCID beige mice purchased from Charles River Laboratories (Sulzfeld, Germany). For orthotopic cell inoculation, H6c7-mock, H6c7-L1CAM, H6c7mono or H6c7co cells were cultured as described above, trypsinized and resuspended in 50 ll Matrigel (BD Biosciences, Heidelberg, Germany) at a concentration of 2 Â 10 6 cells. H6c7co cells that were cocultured for 4 weeks in the presence of PMFs were inoculated together with 4 Â 10 6 murine PMFs in 50 ll Matrigel. All syringes containing Matrigel and cells were placed on ice until intrapancreatic inoculation into the mice (six to eight animals per group). For this purpose, animals were anesthetized and a median laparotomy was performed. Then, cells were inoculated into the pancreatic body to the left of the organ midline. Tumor growth was monitored as recently described (34) by high-resolution ultrasound using a Vevo 770 small animal micro-imaging system from VisualSonics (Toronto, Ontario, Canada).
To investigate whether tumor outgrowth of H6c7co cells can be inhibited by blockade of L1CAM, 2 months after cell inoculation animals were randomized into two groups (n 5 7) and treated either with 10 mg/kg body weight control IgG2a or L1-9.3/2a. All antibodies were diluted in 200 ll 0.9% NaCl and intraperitoneally injected weekly for a time period of 3 months. In all experiments, the last ultrasound examination was done after 5 months just before animals were killed and pancreatic and liver tissues were removed for final determination of the tumor size and preservation in liquid nitrogen.
Immunohistochemistry
Six micrometers thick consecutive cryostat sections were mounted on uncovered glass slides, air-dried for at least 1 h at room temperature and stored at À20°C. For staining procedure, sections were dried again for 30 min at room temperature, fixed in acetone (Merck, Darmstadt, Germany) for 10 min and airdried again for 10 min. Then, slides were washed in phosphate-buffered saline (PBS) and incubated with 4% bovine serum albumin in PBS (Serva, Heidelberg, Germany) for 20 min followed by incubation with the primary antibody for 45 min at room temperature. Primary antibodies were diluted at a final concentration of 10 lg/ml (L1CAM) or 2 lg/ml in PBS þ 1% bovine serum albumin/PBS: mouse IgG1 anti-human L1CAM (clone UJ127; 35), mouse IgG1 anti-human pan-cytokeratin (DakoCytomation, Hamburg, Germany), mouse IgG1 anti-human vimentin (Santra Cruz Biotechnology, Heidelberg, Germany), rabbit-anti-human E-cadherin (Cell Signaling via New England Biolabs, Frankfurt a.M., Germany). Primary antibodies were detected with EnVision conjugated with peroxidase (DakoCytomation) for 30 min. The substrate reaction for peroxidase was performed with the AEC substrate from DakoCytomation according to the instructions of the manufacturer. Afterward, sections were washed in water, counterstained in 50% hemalaun (Merck) and mounted with glycerol-gelatin (Merck). The same protocol was performed for negative controls in which an isotype-matched control antibody was used, which revealed either no staining or only weak background staining.
Statistical analysis
Data are presented as mean ± standard deviation and were analyzed by Student's t-test. A P-value ,0.05 was considered statistically significant.
Results
H6c7 cells exhibiting elevated L1CAM expression and EMTassociated alterations during coculture with PMFs show a decreased apoptosis sensitivity toward death ligands
Our previous results showed that upon coculture with PMFs H6c7 cells acquire a migratory and chemoresistant phenotype (18) thus pointing to the capability of PMFs to induce malignant transformation of H6c7 cells. In support of these findings, H6c7 cells cocultured with PMFs for 4 weeks were characterized by EMT-associated alterations. As shown in Figure 1A , H6c7 cells that were positively stained with a pan-cytokeratin antibody indicating their epithelial origin, exhibited elevated expression levels of L1CAM when cocultured in the presence of PMFs (H6c7co) in contrast to monocultured H6c7 cells (H6c7mono). Moreover, whereas H6c7mono cells were characterized by a transmembraneous expression of E-cadherin and the absence of vimentin, E-cadherin expression was lost in single H6c7co cells and numerous cells exhibited a strong expression of vimentin (indicated by arrows). Coculture-mediated alterations of L1CAM, E-cadherin and vimentin expression in H6c7co cells were confirmed by western blotting (Supplementary Figure 1 , available at Carcinogenesis Online). In addition, numerous H6c7co cells already exhibited a spindle-like cell shape, which is consistent with the above-mentioned alterations. To further elucidate this conversion process, we investigated whether coculture with PMFs also affects proliferation and death ligand-induced apoptosis. Whereas proliferation of H6c7co cells was decelerated rather than accelerated upon coculture with PMFs (data not shown), the apoptotic response toward death ligands was considerably altered. As shown in Figure 1B , H6c7mono cells showed a clear apoptosis induction after stimulation with TRAIL (5.6-fold), TNF-a (2.6-fold) or the CD95 agonistic antibody CH-11 (5.3-fold) as determined by caspase-3/-7 assay. In contrast, H6c7co cells became much less apoptotic in response to these stimuli, in particular after treatment with TRAIL (1.9-fold) and CH-11 (2.2-fold). Similar data were obtained upon coculture with human PMFs (Supplementary Figure 2 , available at Carcinogenesis Online). In order to elucidate whether L1CAM might account for protection from death ligandinduced apoptosis, L1CAM expression was suppressed by siRNA transfection in H6c7co cells during coculture and apoptosis induction after treatment with TRAIL and CH11 was analyzed. As demonstrated in Figure 1C , caspase-3/-7 activity was markedly increased in H6c7co cells after treatment with either apoptotic stimuli when L1CAM L1CAM-mediated tumorigenesis of pancreatic cancer expression was inhibited compared with control-transfected cells.
Overall, these data demonstrate that H6c7 cells undergo EMT-associated alterations in the presence of PMFs, which is associated with an increased expression of L1CAM and an L1CAM-dependent apoptosis resistant phenotype.
H6c7 cells exhibiting elevated L1CAM expression by stable transfection partially exhibit EMT-associated alterations and apoptosis resistance toward death ligands To further confirm the importance of L1CAM in malignant transformation of H6c7 cells, stably L1CAM-overexpressing H6c7 cells were analyzed regarding EMT-associated alterations and death ligandinduced apoptosis. Of the L1CAM transfectants (H6c7-L1CAM) exhibiting strong expression of L1CAM, scattered cells were characterized by an elongated cell shape and a loss of E-cadherin expression similarly to H6c7co cells ( Figure 1D ). In contrast, H6c7-mock cells grown in a dense monolayer were all characterized by a transmembraneous expression of E-cadherin and the absence of L1CAM ( Figure 1D ). In addition, the number of vimentin-expressing cells was slightly increased in the population of H6c7-L1CAM cells compared with H6c7-mock cells albeit weaker than in H6c7co cells. These results were confirmed by western blot analysis demonstrating strong L1CAM expression in H6c7-L1CAM cells. According to the small differences seen in the staining, the expression of E-cadherin was slightly reduced and the expression of vimentin was weakly increased in these cells compared with the mock-transfected cells (Supplementary Figure 3 , available at Carcinogenesis Online). As observed upon coculture with PMFs, L1CAM-overexpressing H6c7 cells showed a reduced sensitivity toward death ligand-induced apoptosis ( Figure 1E ). In particular, caspase-3-/-7 activity was reduced after stimulation with TRAIL compared with control-transfected cells (5.3-fold in mock versus 4.2-fold in H6c7-L1CAM) and CH-11 (5.2-fold in H6c7-mock versus 3.1-fold in H6c7-L1CAM). Similar to the observations upon coculture, L1CAM overexpression did not affect proliferation of H6c7-L1CAM cells (data not shown). Overall, these data indicate that the presence of PMFs or elevated expression of L1CAM confers a reduced apoptosis sensitivity toward death ligandinduced apoptosis in pancreatic ductal epithelial cells.
PMFs increase tumorigenicity of H6c7 cells leading to tumor growth and metastasis in vivo Since PMFs induce EMT-associated alterations in H6c7 cells involving L1CAM-dependent migration and aptoptosis resistance (see above and reference 18), we next analyzed whether the tumorigenic potential of H6c7 cells is increased along with the malignant conversion of the cells. For this purpose, SCID beige mice were orthotopically inoculated with either H6c7 cells alone (H6c7mono) or with a combination of PMFs and cocultured H6c7 cells (H6c7co). As shown in Table I , H6c7mono cells were almost non-tumorigenic confirming previous results (28), only in 2/6 animals tiny lesions of (Table I) . As demonstrated by immunohistochemical stainings with humanspecific antibodies, H6c7co tumors were largely composed of cytokeratin-expressing cells confirming their human and epithelial origin, thus indicating that tumors are mainly composed of H6c7 cells ( Figure 2B) . Moreover, the majority of these H6c7 cells exhibited an elongated cell shape and a strong L1CAM expression. Important to note, E-cadherin expression was less prominent in the cells than cytokeratin or L1CAM indicating the loss E-cadherin expression in tumoral H6c7 cells. Vimentin could be detected in numerous cells within the primary tumor albeit not in the frequency of cytokeratin and L1CAM ( Figure 2B ). Pan-cytokeratin staining of livers revealed that most cells within metastases were indeed H6c7 cells partially expressing L1CAM. Interestingly, all metastasized H6c7 cells expressed E-cadherin, while vimentin expression was predominantly detectable in cells at the margins of the metastases ( Figure 2C ). These data suggest that H6c7 cells become tumorigenic in the presence of PMFs leading to tumor formation and metastasis in vivo.
L1CAM-overexpressing H6c7 cells become tumorigenic in vivo
In order to elucidate whether tumor formation of H6c7 cells depends on L1CAM expression, H6c7 cells stably overexpressing L1CAM (H6c7-L1CAM) or the respective control transfectants (H6c7-mock) were orthotopically inoculated in SCID beige mice. Similarly to H6c7co cells, inoculation of H6c7-L1CAM cells (Table II) led to pancreatic tumor formation detectable in 71% of the animals (5/7). In contrast, H6c7mock cells were almost non-tumorigenic (Table II) besides one animal bearing a tiny pancreatic lesion of unknown specificity. H6c7-L1CAM tumor sizes ranged between 4 and 15 mm 3 (mean ± SD: 6.7 ± 5.6 mm 3 ) (Table II) . Thus, H6c7-L1CAM tumors were much smaller than those arising from inoculation of H6c7co cells and PMFs but could be detected by high-resolution ultrasound examination ( Figure 3A) . Inoculation of H6c7-L1CAM cells resulted in liver metastases in 3/7 animals (Table II) , whereas only in 1/6 animals inoculated with H6c7-mock cells, a liver metastasis was found. The metastases were not detected by high-resolution ultrasound most probably due to difficult scanning conditions because large parts of the liver are located underneath the rib cage but later on after removal of the liver. Overall, these findings point to a role of L1CAM in increasing the tumorigenicity and to a lesser extent the metastatic potential of human pancreatic ductal epithelial cells.
Treatment with L1CAM antibodies inhibits tumor growth and metastasis of tumorigenic H6c7 cells
To support the idea that L1CAM expression confers an increased tumorigenic phenotype of H6c7 cells, H6c7co tumor-bearing animals were treated with the L1CAM-blocking antibody L1-9.3/2a or a control antibody. Antibody treatment started 2 months after cell inoculation when small tumors were detectable by ultrasound examination. One animal treated with the L1-9.3/2a antibody for 9 weeks died due to intestinal obstruction but exhibited neither a pancreatic tumor nor liver metastases. As seen in Table III and Figure 3B , weekly administration of L1CAM-blocking antibodies over a period of 3 months resulted in a complete remission of H6c7co tumor growth and reduced formation of liver metastases in 50% of the animals (Table III) . In contrast, 6/7 H6c7co tumor-bearing mice that were treated with the control antibody exhibited formation of pancreatic tumors ranging between 6 and 468 mm 3 in size (mean ± SD: 112.6 ± 180.4 mm 3 ) (Table III) . In one animal, the pancreatic lesion was too small for further analysis and was therefore excluded from the statistics. Metastases in the liver were not detectable by high-resolution ultrasound but later on during the postmortem analysis in 5/7 animals (Table III) underscoring our previous results (Table I, Figure 2 ). Together with our findings from the H6c7-L1CAM cells, these data confirm that tumor growth and metastasis of pancreatic ductal epithelial cells depends on L1CAM expression and that L1CAM-blocking antibodies are an appropriate tool for anticancer therapy of pancreatic tumors.
Discussion
To date, PDAC is mostly diagnosed in an advanced stage limiting curative therapeutic approaches and PDAC patient's prognosis. Thus, an improved understanding of the early steps of pancreatic tumorigenesis is pivotal to improve diagnostic and therapeutic measures. The substantial impact of PMFs/CAFs on processes involved in PDAC development such as EMT, cell migration and chemoresistance has been demonstrated by us and other groups (5, 6, 8, 15, 16) . In accordance, expression of the PMF marker protein alpha-smooth muscle actin is highly elevated in the stroma of PDAC tissues correlating with short survival of the patients (36) . We recently showed that H6c7 cells cocultured with PMFs acquire a migratory and chemoresistant phenotype through PMF-induced L1CAM expression. Accordingly, elevated L1CAM expression was detected in carcinoma cells in PDAC tissues but also in ductal structures in stroma-enriched chronic pancreatitis indicating that PMFs might be involved in malignant transformation of pancreatic ductal epithelial cells (18) . We are now showing that H6c7 cells become tumorigenic in the presence of PMFs resulting in the outgrowth of pancreatic tumors and liver metastases, whereas H6c7 cells alone were non-tumorigenic confirming the results by Furukawa et al. (28) . H6c7co tumors were strongly stained by a human pan-cytokeratin antibody indicating that they are largely composed of human cells of epithelial origin. In search for the mechanisms leading to pancreatic tumorigenesis, mutational activation of the k-ras gene has gained much attention since mutant k-ras is present already in early PanINs and later on in 90% of PDAC (2,4). Hence, Qian et al. could demonstrate that expression of mutant k-ras in H6c7 cells that per se exhibit none of the mutations commonly detected in PDAC (27, 28) induced tumor formation in 50% of subcutaneously inoculated SCID mice (37) . Similar results have been demonstrated in rat models (38, 39) . Moreover, development of human PDAC was recapitulated in different transgenic mouse models, e.g. by expression of endogenous k-ras G12D induced during early stages of embryonic pancreatic development in the mouse model of Hingorani et al. (40) . However, expression of k-ras G12D in adult mice more closely reflecting the situation in humans did not result in PanIN formation and 
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invasive PDAC unless a mild chronic pancreatitis was induced (9) . Altogether these data suggest that genetic alterations alone do not necessarily lead to PDAC development and that context-derived factors such as stromal cells and their secreted factors are likewise important. This is supported by our own findings showing that already an indirect coculture with PFMs leads to EMT in H6c7 and PDAC cells along with a migratory and apoptosis resistant phenotype, which highly depends on humoral factos such as TGF-b1, IL-1b and nitric oxide (8, 18, 30) . Moreover, all these factors have been described as potential inducers of L1CAM (18, 22) . The observation that elevated L1CAM expression in H6c7 cells essentially contributes to the PMFinduced migratory and apoptosis resistant phenotype in vitro points to an important role of this molecule in the malignant transformation of pancreatic ductal epithelial cells.
In line with this, H6c7 cells in H6c7co tumors exhibited a high L1CAM expression along with a marked expression of vimentin and a reduced expression of E-cadherin in numerous cells pointing to a continuation of EMT in H6c7co tumors. Interestingly, the majority of H6c7 cells in PDAC liver metastases expressed E-cadherin, whereas vimentin expression was mainly detected in cells located at the margins of the metastases. Similarly, E-cadherin expression in metastases but not in primary tumors has been reported by various groups (41) (42) (43) . Overall, these data are consistent with the idea of a mesenchymal-epithelial transition by which metastasized tumor cells re-express E-cadherin to seed in the new tissue and to establish metastatic foci (44) .
Gavert et al. (20) already demonstrated that subcutaneous inoculation of L1CAM-overexpressing NIH3T3 cells into nude mice results in the formation of larger tumors than inoculation of control-transfected cells. Our study shows that stable overexpression of L1CAM led to tumor formation of H6c7 cells in 5/7 animals, similarly seen after co-inoculation with PMFs, whereas no pancreatic tumors developed after inoculation of the control transfectants. However, H6c7-L1CAM tumors were much smaller in size and the incidence of metastases in the liver was lower compared with tumors and metastases in animals after inoculation of H6c7co cells. The observation that inoculation of H6c7-mock cells resulted in the formation of metastases at least in one animal might be explained by the fact that these cells had undergone a double retroviral transduction procedure (first time for immortalization and second time for stable transfection with the control vector for L1CAM) increasing the tumorigenic potential of the cells. Overall, these data indicate that expression of L1CAM substantially increases the tumorigenicity of H6c7 cells but is not sufficient to start metastasis in full extent as occurring under the influence of PMFs. Supporting this idea, expression of vimentin was much less pronounced in H6c7-L1CAM cells compared with H6c7-mock cells. Gavert et al. (45, 46) recently showed that L1CAM confers a motile phenotype in colon cancer cells resulting in metastasis to the liver but without inducing EMT and stem cell properties. These results suggest that the impact of L1CAM on metastasis is (i) either more prominent in the tumorigenesis of the colon than that of the pancreas or (ii) is more pronounced in fully transformed cancer cells than in epithelial cells where transformation still commences. Accordingly, treatment of H6c7co tumor-bearing mice 
with L1CAM-blocking antibodies completely abolished formation of primary tumors but reduced liver metastasis only in 50% of the animals. Thus, L1CAM seemed to be sufficient for initial tumor formation and growth of pancreatic ductal epithelial cells but the process of metastasis apparently requires additional alterations and/or signals which are provided, e.g. by the stromal microenvironment. Stromal cells such as PMFs (and later on CAFs) are known to promote cell migration and metastasis by producing a plethora of cytokines, growth factors and proteases which enhance the migratory potential of epithelial/carcinoma cells and help to digest the extracellular matrix (6, 8, 16, 47) .
Bao et al. (48) reported elevated L1CAM expression on CD133þ cancer stem cells in gliomas and targeting of L1CAM in these cells significantly reduced tumor outgrowth in immunocompromised mice supporting the view that L1CAM is able to confer a tumorigenic phenotype. Moreover, this group showed that L1CAM is essentially involved in the regulation of DNA damage checkpoint responses thereby determining radiosensitivity of glioblastoma stem cells (49) . Under physiological conditions, these checkpoints are tightly regulated and exert cytoprotective functions to promote cell survival (50) . However, dysregulation of these checkpoints, e.g. as a result of sustained L1CAM expression might promote cell survival of damaged cells that otherwise would have been eliminated in order to prevent proliferation of genetically altered cells and tumorigenesis. Besides enhanced DNA repair, the protection from apoptosis induction might be another mechanism by which cells harboring DNA mutations can survive and expand. Accordingly, we could demonstrate that H6c7 cells either cocultured in the presence of PFMs or stably transduced with recombinant L1CAM acquired a resistant phenotype toward death ligand-induced apoptosis in particular after stimulation of CD95 and TRAIL. To underscore the importance of L1CAM in apoptosis resistance of tumor cells and the suitability of L1CAM antibodies as therapeutic tool, a recent study demonstrated that L1CAM-dependent chemoresistance can be overcome by antibody-mediated blockade of L1CAM in PDAC and ovarian carcinoma cells in vivo resulting in significantly reduced tumor growth (H. Schäfer et al., unpublished results).
In summary, the present study demonstrates that the tumorigenic potential of pancreatic ductal epithelial cells is highly increased in the presence of PMFs promoting tumor growth and metastasis. Elevated expression of L1CAM plays an essential role in this scenario probably by conferring a profound apoptosis protection allowing survival and expansion of genetically altered cells. Hence, L1CAM expression in ductal structures of chronic pancreatitis as reported previously (18) has to be seriously regarded as a first step of tumorigenesis.
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